Rickie Isahdie

Mr. Rickie Isahdie


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2026 in Organoids
Verified
Journal Article
Open access
PDF file
Henkie Isahwan Ahmad Mulyadi LaiHenkie Isahwan Ahmad Mulyadi Lai
Henkie Isahwan Ahmad Mulyadi Lai
RIRickie Isahdie
Rickie Isahdie
SVSuci Ventasamia
Suci Ventasamia
SPSukrit Promtang
Sukrit Promtang
Natural products offer diverse chemical structures and pharmacological activities for therapeutic discovery. Their translation benefits from evidence that connects a reproducible preparation with relevant exposure and a clearly defined biological response. Organoids can strengthen this evidence by providing tissue architecture, cellular diversity, and donor-specific features suited to focused experimental questions. This critical narrative review uses a structured literature search to synthesize representative natural-product studies across tumor, intestinal, hepatic, renal, pulmonary, cortical, retinal, and cardiac platforms. Direct organoid evidence, findings from related three-dimensional models, and prospective applications are distinguished by material, species, derivation, exposure, and endpoint. The selected examples illustrate these distinctions rather than provide a comprehensive evidence map. We propose an exposure-aware conceptual decision framework linking material identity, assay compatibility, exposure plausibility, model fitness, functional activity, and context-specific validation. Six gates guide advance, iterate, or stop/redirect decisions and make the evidence supporting each claim explicit. The framework provides a practical structure for study design and reporting, with prospective evaluation as the next step. Roselle serves as an illustrative botanical example for future organoid testing. Used alongside analytical studies, two-dimensional cultures, animal models, and clinical research, qualified organoids can help move natural-product discovery toward reproducible, tissue-level, and decision-relevant evidence.

9 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Henkie Isahwan Ahmad Mulyadi LaiHenkie Isahwan Ahmad Mulyadi Lai
Henkie Isahwan Ahmad Mulyadi Lai
RIRickie Isahdie
Rickie Isahdie
RRRushduddin Al Jufri Roosli
Rushduddin Al Jufri Roosli
Henkie Isahwan Ahmad Mulyadi LaiHenkie Isahwan Ahmad Mulyadi Lai
Henkie Isahwan Ahmad Mulyadi Lai
YYYusmi Mohd Yunus
Yusmi Mohd Yunus
The convergence of nanomedicine and organoid technology has emerged as a promising frontier in biomedical science, offering improved platforms for disease modelling, drug testing, and precision therapy. However, the interdisciplinary landscape of this research remains underexplored. This study conducted a scientometric analysis of over 300 Scopus-indexed publications from 2015 to 2025 to characterize trends, collaborations, and thematic structures at the intersection of nanomedicine and organoid research. Using VOSviewer, we analyzed keyword co-occurrences, citation networks, and international co-authorships. Results reveal a substantial increase in publications over the past decade, with notable surges in topics such as tumor microenvironment, immune checkpoint therapy, and RNA sequencing. Core themes identified include tissue engineering, oncology modelling, regenerative medicine, and transcriptomics. The United States and China emerged as leading contributors, with growing global collaboration patterns. Keyword evolution analysis indicated a shift from foundational 3D culture and material optimization to more application-driven focuses in personalized medicine and environmental nanotoxicology. These findings highlight the field’s maturation into a multidisciplinary and translational domain. This overview provides valuable insights for guiding future research directions, international partnerships, and the development of clinically relevant organoid-based nanomedicine platforms.